<DOC>
	<DOCNO>NCT00503113</DOCNO>
	<brief_summary>This 3 arm study evaluate renal safety administration intravenous ( iv ) injection infusion Bonviva , compare oral alendronate , patient postmenopausal osteoporosis , increase risk renal disease . Patients randomize receive Bonviva 3mg intravenous ( iv ) ) injection b ) infusion every 3 month , alendronate 70mg per oral ( po ) weekly . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Bonviva ( Ibandronate ) Alendronate Renal Function Postmenopausal Women With Osteoporosis High Risk Renal Disease .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>female patient , &gt; =60 year age ; &gt; =5 year postmenopausal ; confirm osteoporosis , increase risk renal disease . inability stand sit upright 30 minute ; hypersensitivity bisphosphonates ; malignant disease ( successfully resect basal cell cancer ) within previous 10 year , breast cancer diagnose within previous 20 year ; previous administration i.v . bisphosphonate ; oral bisphosphonate treatment study medication within 30 day prior baseline dose visit study ; history major upper gastrointestinal disease .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>